Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 15,384

Document Document Title
WO/2023/155927A1
The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...  
WO/2023/158862A2
The invention provides novel modulators of STING (Stimulator of Interferon Genes) and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as cancer, in...  
WO/2023/159086A1
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula I : (I) wherein the variables of Formula I are defined herein. This disclosure also provides...  
WO/2023/150899A1
Novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions.  
WO/2023/151642A1
Provided herein are compounds having the following structure, wherein the substituents are as defined herein, compositions comprising an effective amount of a compound, and methods for modulating activity of an immune cell.  
WO/2023/152063A1
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, particularly organic electroluminescent devices, containing these compounds.  
WO/2023/154905A1
The disclosure provides compounds of Formulae (I) or (II), or a pharmaceutically acceptable salt thereof, (I), or (II) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compoun...  
WO/2023/153739A1
The present invention relates to a novel compound and uses thereof and, more specifically, to a compound capable of labeling a biomolecule (e.g. nucleic acid, protein, etc.), a composition for labeling or detecting a biomolecule comprisi...  
WO/2023/154499A1
Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.  
WO/2023/154962A1
The disclosure relates generally novel inhibitors of human cGAS and methods of treating cGAS -related diseases or disorders in a patient.  
WO/2023/151513A1
The invention provides novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions (e.g., cancer).  
WO/2023/153844A1
The present specification relates to a heterocyclic compound of chemical formula 1, and a composition for forming an organic light-emitting element and an organic material layer, wherein the composition comprises the heterocyclic compound.  
WO/2023/152346A1
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.  
WO/2023/154519A1
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.  
WO/2023/154314A1
The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharma...  
WO/2023/150056A1
Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula (A), as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein ...  
WO/2023/150776A1
The present disclosure provides water-soluble and low-aggregation NIR- and SWIR- active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.  
WO/2023/150681A1
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.  
WO/2023/147149A1
Provided is an anhydrous crystalline form of Pelabresib as well as its use for treating conditions associated with BET proteins.  
WO/2023/141705A1
The present disclosure relates to the treatment of prostate cancer using a combination of cepharanthine or a pharmaceutically acceptable salt thereof, and a taxane, optionally paclitaxel, docetaxel, or cabazitaxel. Also described herein ...  
WO/2023/143154A1
Disclosed are a pharmaceutical composition, a method for preparing same, and use thereof. The composition comprises the following components: an antibody-drug conjugate, a buffer system, a lyoprotectant, and a surfactant. The pharmaceuti...  
WO/2023/146990A1
Provided are compounds of Formula (A) and Formula (I): (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ring A, RB, Ring B, R1, R2 and n ...  
WO/2023/144559A1
The present invention relates to compounds of formula I shown below: wherein R1, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...  
WO/2023/143208A1
The present invention provides a preparation method for a drug linker conjugate. The present invention further provides a preparation method for an intermediate or a salt thereof, and a use of an intermediate or a salt thereof. The raw m...  
WO/2023/143393A1
Disclosed are a tricyclic compound, and a preparation method therefor and the use thereof. The tricyclic compound has a structure as shown in formula I, and can be used for treating various mental diseases and neurodegenerative diseases ...  
WO/2023/144160A1
The invention provides new heterocyclic compounds having the general formula (I) wherein A and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...  
WO/2023/143623A1
Disclosed are a quinoline compound and the use thereof. The quinoline compound is a compound as represented by formula (I), formula (II) or formula (III), a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer ther...  
WO/2023/147418A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, togeth...  
WO/2023/144332A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer and/or the treatment or prevention of a viral infection, wherein A1, A2, L1 and R1 have meanings as prov...  
WO/2023/139085A1
The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2', R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2023/138601A1
The present invention discloses a bridged ring-substituted heteroaryl-pyran derivative and a use thereof, and in particular discloses a compound as represented in formula (VI) or a pharmaceutically acceptable salt thereof.  
WO/2023/140710A1
The invention relates to a light-emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - a first chemical moiety with a structure of formula I: And - ...  
WO/2023/139534A1
Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).  
WO/2023/139241A1
The present invention concerns inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof. Specifically, the invention provides compounds according to formula (I), including stereoisomers, pharmaceutically acceptable ...  
WO/2023/138254A1
The present invention relates to a heterocyclic compound, an organic electroluminescent material, and an organic electroluminescent element. The structure of the heterocyclic compound is as shown in formula (I). The heterocyclic compound...  
WO/2023/138362A1
The present invention relates to a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to WEE1 activity.  
WO/2023/135564A1
The present invention relates to a compound represented by chemical formula 1, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutical composition comprising same.  
WO/2023/134647A1
Provided are a piperazino ring derivative represented by formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition containing said compound, as well as the use of the compoun...  
WO/2023/136334A1
This method for producing a compound represented by formula (I) involves forming at least one bond between a carbon atom and a nitrogen atom in an aromatic ring of the compound represented by formula (I) through a reaction using a pallad...  
WO/2023/137026A1
Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and/or derivatives. In certain embodiments, provided are...  
WO/2023/134266A1
A 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a s...  
WO/2023/134374A1
Disclosed are a pyrimido-heterocyclic compound a preparation method, and a use, and specifically disclosed are a pyrimido-heterocyclic compound as represented by general formula (I), or a pharmaceutically acceptable salt thereof, or an e...  
WO/2023/132369A1
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...  
WO/2023/131868A1
The present invention relates to heterocyclic compounds and methods which may be useful as inhibitors of GLUT9 for the treatment or prevention of hyperuricemia and gout.  
WO/2023/131632A1
The invention provides a novel formulation of Atrorosins, and Atrorosin Lakes. Additionally,improved methods for their production by binding to inert metallic mordant is provided; and further the uses of the novel lakes as a coloring age...  
WO/2023/133271A1
The present disclosure relates to compounds of Formula (III): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for i...  
WO/2023/125530A1
Antibody-drug conjugate compounds comprising a linker and methods of using such compounds are provided.  
WO/2023/127809A1
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...  
WO/2023/125918A1
The present invention discloses a DNA polymerase theta inhibitor and the use thereof. Specifically, the present invention provides a compound as shown in formula (I) or formula (II), or a tautomer thereof, a stereoisomer thereof, a pharm...  
WO/2023/125841A1
A compound of formula (I) as a Polθ inhibitor, a preparation method therefor, and a use thereof.  

Matches 251 - 300 out of 15,384